![SION - Sionna Therapeutics Inc - Stock Price Chart]() |
Market Cap | 924.85M | EPS (ttm) | - |
P/E | - | EPS this Y | 83.43% |
Forward P/E | - | EPS next Y | -8.40% |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | 40.90% |
P/B | 2.63 | EPS Q/Q | - |
Dividend | - | Sales Q/Q | - |
Insider Own | 46.56% | Inst Own | 54.08% |
Insider Trans | 20.75% | Inst Trans | 39.33% |
Short Float | 12.02% | Earnings | May 12/b |
Analyst Recom | 1.00 | Target Price | 38.50 |
Avg Volume | 180.78K | 52W Range | 7.26 - 25.19 |
|
|
|
Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a robust pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
TPG GP A, LLC | 10% Owner | Jun 27 '25 | Buy | 15.84 | 60,000 | 950,400 | 6,744,962 | Jul 01 05:03 PM | TPG GP A, LLC | 10% Owner | Feb 10 '25 | Buy | 18.00 | 1,125,000 | 20,250,000 | 6,684,962 | Feb 12 05:21 PM | RA CAPITAL MANAGEMENT, L.P. | Director | Feb 10 '25 | Buy | 18.00 | 1,125,000 | 20,250,000 | 6,923,365 | Feb 10 05:04 PM | ORBIMED ADVISORS LLC | Director | Feb 10 '25 | Buy | 18.00 | 550,000 | 9,900,000 | 3,704,959 | Feb 10 04:28 PM | Thompson Peter A. | Director | Feb 10 '25 | Buy | 18.00 | 550,000 | 9,900,000 | 3,704,959 | Feb 10 04:05 PM |
|
|
 |
![ANNX - Annexon Inc - Stock Price Chart]() |
Market Cap | 299.52M | EPS (ttm) | -1.17 |
P/E | - | EPS this Y | -45.07% |
Forward P/E | - | EPS next Y | 1.20% |
PEG | - | EPS past 5Y | -0.09% |
P/S | - | EPS next 5Y | 2.82% |
P/B | 1.23 | EPS Q/Q | -78.85% |
Dividend | - | Sales Q/Q | - |
Insider Own | 12.93% | Inst Own | 87.98% |
Insider Trans | -0.27% | Inst Trans | -5.92% |
Short Float | 10.60% | Earnings | May 12/b |
Analyst Recom | 1.00 | Target Price | 11.60 |
Avg Volume | 1.60M | 52W Range | 1.28 - 7.85 |
|
|
|
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Carson William H. | Director | Jun 30 '25 | Buy | 2.46 | 4,115 | 10,123 | 29,715 | Jul 01 04:55 PM | Dananberg Jamie | CHIEF MEDICAL OFFICER | Feb 18 '25 | Sale | 2.96 | 5,521 | 16,342 | 33,479 | Feb 20 04:54 PM | ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | Feb 18 '25 | Sale | 2.97 | 5,515 | 16,380 | 83,814 | Feb 20 04:52 PM | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Feb 18 '25 | Sale | 2.91 | 8,345 | 24,284 | 61,237 | Feb 20 04:51 PM | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Feb 18 '25 | Sale | 2.95 | 6,618 | 19,523 | 86,579 | Feb 20 04:49 PM |
|
|
 |
![KFS - Kingsway Financial Services Inc - Stock Price Chart]() |
Market Cap | 467.75M | EPS (ttm) | -0.37 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -5.78% |
P/S | 4.08 | EPS next 5Y | - |
P/B | 80.49 | EPS Q/Q | -65.23% |
Dividend | - | Sales Q/Q | 7.71% |
Insider Own | 29.70% | Inst Own | 45.97% |
Insider Trans | -11.89% | Inst Trans | 11.99% |
Short Float | 2.42% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 66.77K | 52W Range | 7.06 - 16.62 |
|
|
|
Kingsway Financial Services, Inc. operates as a holding company. The firm engages in the provision of financial services. It operates through the following segments: Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment includes excellent businesses in the Automotive and HVAC markets. It continues to expand its portfolio of high-quality operating companies through organic growth and disciplined M&A. The Kingsway Search Xcelerator segment is involved in review of billing rates and product prices are performed regularly and rates can be adjusted to reflect prevailing marketing expectations. The company was founded on September 19, 1989 and is headquartered in Chicago, IL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
STILWELL JOSEPH | Director | Jun 27 '25 | Sale | 14.03 | 128,243 | 1,799,596 | 487,713 | Jul 01 05:52 PM | STILWELL JOSEPH | Director | Jun 30 '25 | Sale | 13.90 | 32,978 | 458,556 | 481,817 | Jul 01 05:52 PM | Fitzgerald John Taylor Maloney | President and CEO | Jul 01 '25 | Buy | 14.02 | 179 | 2,510 | 1,529,876 | Jul 01 04:52 PM | Hansen Kent A | CFO & EVP | Jul 01 '25 | Buy | 14.02 | 111 | 1,556 | 135,248 | Jul 01 04:51 PM | Hansen Kent A | CFO & EVP | Jun 13 '25 | Buy | 13.77 | 114 | 1,570 | 135,137 | Jun 16 04:00 PM |
|
|
|  |
![SWZ - Total Return Securities Fund - Stock Price Chart]() |
Market Cap | 81.58M | EPS (ttm) | - |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | - |
Dividend | 4.55% | Sales Q/Q | - |
Insider Own | - | Inst Own | - |
Insider Trans | - | Inst Trans | - |
Short Float | 0.10% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 81.43K | 52W Range | 5.09 - 6.71 |
|
|
|
The Swiss Helvetia Fund Inc. is a closed-ended equity mutual fund launched and managed by Schroder Investment Management North America Inc. The fund invests in public equity markets of Switzerland. It seeks to invest in stocks of companies operating across diversified sectors. The fund primarily invests in value stocks of companies across all market capitalizations. It employs fundamental analysis with a bottom-up stock picking approach, focusing on factors such as capital appreciation, income, economic and industry trends, quality of management, financial condition, business plan, industry and sector market position, dividend payout ratio, and corporate governance to create its portfolio. The fund benchmarks the performance of its portfolio against the S&P 500 Index and MSCI EAFE Index. It was previously known as The Helvetia Fund, Inc. The Swiss Helvetia Fund Inc. was formed in October 24, 1986 and is domiciled in the United States. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
SELL MORITZ A | Director | Jun 30 '25 | Buy | 6.34 | 1,815 | 11,507 | 3,400 | Jul 01 04:39 PM | HELLERMAN GERALD | Director | Apr 02 '25 | Sale | 9.24 | 41 | 379 | 5,283 | Apr 03 04:05 PM | GOLDSTEIN PHILLIP | Director | Jan 17 '25 | Sale | 8.45 | 4,535 | 38,321 | 12,248 | Jan 21 04:14 PM |
|
|
 |
![SPG - Simon Property Group, Inc - Stock Price Chart]() |
Market Cap | 62.24B | EPS (ttm) | 6.69 |
P/E | 24.66 | EPS this Y | -12.44% |
Forward P/E | 24.06 | EPS next Y | 7.91% |
PEG | - | EPS past 5Y | 2.13% |
P/S | 10.38 | EPS next 5Y | -1.55% |
P/B | 21.00 | EPS Q/Q | -38.19% |
Dividend | 5.14% | Sales Q/Q | 2.11% |
Insider Own | 0.93% | Inst Own | 92.74% |
Insider Trans | 0.14% | Inst Trans | 2.33% |
Short Float | 1.09% | Earnings | May 12/a |
Analyst Recom | 2.10 | Target Price | 183.06 |
Avg Volume | 1.78M | 52W Range | 136.34 - 190.13 |
|
|
|
Simon Property Group, Inc. is a self-administered and self-managed real estate investment trust, which engages in the ownership, development, and management of shopping, dining, entertainment, and mixed-used destinations, which consist primarily of malls, Premium Outlets, and the Mills. The company was founded by Fred Simon, Herbert Simon and Melvin Simon in 1993 and is headquartered in Indianapolis, IN. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
STEWART MARTA R | Director | Jun 30 '25 | Buy | 159.29 | 208 | 33,132 | 16,080 | Jul 01 04:30 PM | Smith Daniel C. | Director | Jun 30 '25 | Buy | 159.29 | 378 | 60,212 | 31,998 | Jul 01 04:28 PM | SELIG STEFAN M | Director | Jun 30 '25 | Buy | 159.29 | 219 | 34,885 | 31,881 | Jul 01 04:26 PM | Roe Peggy Fang | Director | Jun 30 '25 | Buy | 159.29 | 86 | 13,699 | 6,650 | Jul 01 04:23 PM | RODKIN GARY M | Director | Jun 30 '25 | Buy | 159.29 | 246 | 39,185 | 19,010 | Jul 01 04:21 PM |
|
|
|  |
![CDXS - Codexis Inc - Stock Price Chart]() |
Market Cap | 213.74M | EPS (ttm) | -0.99 |
P/E | - | EPS this Y | 22.15% |
Forward P/E | - | EPS next Y | 17.01% |
PEG | - | EPS past 5Y | -33.31% |
P/S | 4.29 | EPS next 5Y | 41.30% |
P/B | 4.31 | EPS Q/Q | -52.40% |
Dividend | - | Sales Q/Q | -55.82% |
Insider Own | 3.23% | Inst Own | 83.26% |
Insider Trans | 140.25% | Inst Trans | 7.29% |
Short Float | 7.93% | Earnings | May 14/a |
Analyst Recom | 1.57 | Target Price | 7.08 |
Avg Volume | 851.34K | 52W Range | 1.90 - 6.08 |
|
|
|
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Opaleye Management Inc. | 10% Owner | Jun 27 '25 | Buy | 2.39 | 100,000 | 239,000 | 12,350,000 | Jul 01 04:05 PM | Opaleye Management Inc. | 10% Owner | Jun 12 '25 | Buy | 2.25 | 100,000 | 225,000 | 12,100,000 | Jun 16 04:59 PM | Opaleye Management Inc. | 10% Owner | Jun 13 '25 | Buy | 2.23 | 99,102 | 220,997 | 12,199,102 | Jun 16 04:59 PM | Opaleye Management Inc. | 10% Owner | Jun 16 '25 | Buy | 2.24 | 50,898 | 114,012 | 12,250,000 | Jun 16 04:59 PM | Opaleye Management Inc. | 10% Owner | May 23 '25 | Buy | 2.36 | 2,320,000 | 5,475,200 | 11,995,000 | May 28 04:05 PM |
|
|
 |
![OCSL - Oaktree Specialty Lending Corp - Stock Price Chart]() |
Market Cap | 1.22B | EPS (ttm) | 0.12 |
P/E | 115.42 | EPS this Y | -16.65% |
Forward P/E | 8.24 | EPS next Y | -9.54% |
PEG | - | EPS past 5Y | - |
P/S | 3.45 | EPS next 5Y | - |
P/B | 0.83 | EPS Q/Q | - |
Dividend | 13.83% | Sales Q/Q | -17.50% |
Insider Own | 0.30% | Inst Own | 38.29% |
Insider Trans | 19.29% | Inst Trans | - |
Short Float | 1.38% | Earnings | May 01/b |
Analyst Recom | 2.71 | Target Price | 14.30 |
Avg Volume | 727.58K | 52W Range | 12.50 - 18.70 |
|
|
|
Oaktree Specialty Lending Corporation is a business development company. The fund specializing in investments in middle market, bridge financing, first and second lien debt financing, unsecured and mezzanine loan, mezzanine debt, senior and junior secured debt, expansions, sponsor-led acquisitions, preferred equity, and management buyouts in small and mid-sized companies. It seeks to invest in education services, business services, retail and consumer, healthcare, manufacturing, food and restaurants, construction and engineering. The firm also seeks investment in media, advertising sectors, software, IT services, pharmaceuticals, biotechnology, real estate management and development, chemicals, machinery, and internet and direct marketing retail sectors. It invests between $5 million to $75 million principally in the form of one-stop, first lien, and second lien debt investments, which may include an equity co-investment component in companies. The firm invest in companies having enterprise value between $20 million and $150 million and EBITDA between $3 million and $50 million. The fund has a hold size of up to $75 million and may underwrite transactions up to $100 million. It primarily invests in North America. The fund seeks to be a lead investor in its portfolio companies. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Gero Deborah Ann | Director | Jun 30 '25 | Buy | 13.70 | 2,500 | 34,250 | 22,411 | Jul 01 04:05 PM | Panossian Armen | See Remarks | May 15 '25 | Buy | 14.13 | 8,000 | 113,040 | 20,789 | May 19 06:06 AM | CALDWELL PHYLLIS R | Director | May 07 '25 | Buy | 13.32 | 2,000 | 26,650 | 18,000 | May 08 06:03 AM | Jacobson Craig A | Director | May 06 '25 | Buy | 13.41 | 14,910 | 199,919 | 71,667 | May 07 04:10 PM | CALDWELL PHYLLIS R | Director | Feb 25 '25 | Buy | 15.83 | 2,500 | 39,575 | 16,000 | Feb 26 04:15 PM |
|
|
|  |
![PRME - Prime Medicine Inc - Stock Price Chart]() |
Market Cap | 498.92M | EPS (ttm) | -1.66 |
P/E | - | EPS this Y | 23.33% |
Forward P/E | - | EPS next Y | 20.83% |
PEG | - | EPS past 5Y | -124.13% |
P/S | 129.59 | EPS next 5Y | 18.30% |
P/B | 4.66 | EPS Q/Q | 9.47% |
Dividend | - | Sales Q/Q | 146.02% |
Insider Own | 60.65% | Inst Own | 28.99% |
Insider Trans | 0.41% | Inst Trans | -6.37% |
Short Float | 35.79% | Earnings | May 08/b |
Analyst Recom | 1.73 | Target Price | 7.69 |
Avg Volume | 2.56M | 52W Range | 1.11 - 6.75 |
|
|
|
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Liu David R. | 10% Owner | Jun 30 '25 | Buy | 2.52 | 21,000 | 52,830 | 20,240,945 | Jul 01 04:03 PM | Liu David R. | 10% Owner | Jun 23 '25 | Buy | 2.16 | 21,000 | 45,402 | 20,219,945 | Jun 23 04:33 PM | Liu David R. | 10% Owner | Jun 16 '25 | Buy | 1.49 | 21,000 | 31,196 | 20,198,945 | Jun 16 05:14 PM | Liu David R. | 10% Owner | Jun 11 '25 | Buy | 1.60 | 21,000 | 33,590 | 20,177,945 | Jun 12 04:49 PM | Brudnick Richard | Chief Business Officer | May 20 '25 | Buy | 1.19 | 20,000 | 23,790 | 20,000 | May 22 04:22 PM |
|
|
 |
![PLUR - Pluri Inc - Stock Price Chart]() |
Market Cap | 45.35M | EPS (ttm) | -3.61 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | 29.51% |
P/S | 44.03 | EPS next 5Y | 33.58% |
P/B | - | EPS Q/Q | 7.62% |
Dividend | - | Sales Q/Q | 501.41% |
Insider Own | 46.69% | Inst Own | 17.39% |
Insider Trans | 36.42% | Inst Trans | 119.45% |
Short Float | 0.80% | Earnings | May 08 |
Analyst Recom | 1.00 | Target Price | 12.00 |
Avg Volume | 36.92K | 52W Range | 3.33 - 7.13 |
|
|
|
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The firm focuses on the research, development, and manufacturing of cell-based products and technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Manieu Alexandre Weinstein | Director | Apr 28 '25 | Buy | 4.61 | 976,139 | 4,500,001 | 931,246 | Jul 01 04:00 PM |
|
|
 |
![EONR - EON Resources Inc - Stock Price Chart]() |
Market Cap | 7.37M | EPS (ttm) | -0.89 |
P/E | - | EPS this Y | 75.13% |
Forward P/E | - | EPS next Y | 40.67% |
PEG | - | EPS past 5Y | - |
P/S | 0.38 | EPS next 5Y | - |
P/B | 0.60 | EPS Q/Q | 87.26% |
Dividend | - | Sales Q/Q | -11.94% |
Insider Own | 33.83% | Inst Own | 1.76% |
Insider Trans | -13.25% | Inst Trans | -24.76% |
Short Float | 12.98% | Earnings | May 23/b |
Analyst Recom | 1.00 | Target Price | 2.00 |
Avg Volume | 5.46M | 52W Range | 0.33 - 2.92 |
|
|
|
EON Resources, Inc. engages in the acquisition, development, exploration, production, and divestiture of oil and natural gas properties in the Permian Basin. The company was founded in February 2017 and is headquartered in Houston, TX. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Salvucci Joseph V Sr | Director | Jun 30 '25 | Buy | 0.34 | 123,951 | 41,957 | 1,629,121 | Jul 01 03:30 PM | Salvucci Joseph V Jr | Director | Jun 27 '25 | Buy | 0.35 | 15,000 | 5,217 | 147,784 | Jun 30 03:30 PM | Salvucci Joseph V Sr | Director | Jun 27 '25 | Buy | 0.37 | 100,000 | 36,640 | 1,505,170 | Jun 30 11:23 AM | Caravaggio Dante | Chief Executive Officer | Jun 27 '25 | Buy | 0.35 | 3,000 | 1,045 | 564,440 | Jun 27 05:35 PM | Trotter Mitchell | Chief Financial Officer | Jun 27 '25 | Buy | 0.35 | 15,000 | 5,232 | 54,398 | Jun 27 03:14 PM |
|
|
|